Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
54
天
Investigation of biomarkers for azole antifungal-induced liver injury using primary human hepatocyte spheroids
作者
Masaki Kumondai; Ayaka Yagi; Masahiro Watanabe; Yanlin Lyu; Ryosuke Segawa; Mayumi Sato; Ryo Tadakuma; Kenji Inoue; Hideki Watanabe; Masahiro Takeda; Yoshiteru Ohshima; Masamitsu Maekawa; Nariyasu Mano展开收起
作者单位
Department of Pharmaceutical Sciences, Tohoku University Hospital, Aoba-ku, Sendai, Japan; Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai, Japan; Drug Development Research Laboratories, Kyoto R&D Center, Maruho Co, Ltd, Kita-ku, Osaka, Japan; Head Office for Open Innovation Business Development Strategy, Tohoku University, Aoba-ku, Sendai, Japan展开收起
172
天
Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants
作者
Andy Sykes; Zhoupeng Zhang; Jana Skeete; Pradeep Sharma; Stephen Wilkinson; Ryan Bragg; Sasha McClain; Malin Gränfors; Isobel Leddin; Christopher Bailey; Bistra Kirova; Nand Singh; Karthick Vishwanathan; Niresh Hariparsad展开收起
作者单位
Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge, UK; Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, Waltham, Massachusetts; Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, Cambridge, UK; Early Chemical Development, Pharmaceutical Sciences, AstraZeneca, Cambridge, UK; Late Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland; Early Product Development and Manufacturing, Pharmaceutical Sciences, AstraZeneca, Gothenburg, Sweden; Late Development, Oncology R&D, AstraZeneca, Cambridge, UK; Integrated Bioanalysis, AstraZeneca, Cambridge, UK; Oncology Patient Safety, Oncology R&D, AstraZeneca, Cambridge, UK; Medical Department, Quotient Sciences, Ruddington, Nottingham, UK; Clinical Pharmacology and Pharmacometrics, AstraZeneca, Waltham, Massachusetts展开收起
134
天
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天